Melbourne, Australia; 5 March 2024 – Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, confirms that the first patient has been enrolled and treated in its Phase 2 clinical trial of CYP-001 in high-risk acute graft versus host disease (aGvHD). [Read more…]
Charles River Collaborates with Pluristyx, Expanding its Portfolio of Human Pluripotent Stem Cells
The addition of ES cells and iPSCs will enhance Charles River’s portfolio of powerful research tools supporting acceleration of therapeutic development.
WILMINGTON, Mass., February 20, 2024 – Charles River Laboratories International, Inc. (NYSE: CRL) announced that it has entered into an agreement with Pluristyx Inc., a leading provider of tools, technologies, and services for the development of cell therapies. The collaboration provides Charles River with broad access to highly characterized and unique stem cell lines, including high-quality embryonic stem (ES) cells and induced pluripotent stem cells (iPSCs) as research tools to support development of new therapeutics. [Read more…]
Cord Blood Registry® (CBR®) by CooperSurgical® and Fulgent Genetics Launch Innovative Genetic Testing
Testing offers CBR families the opportunity to proactively seek additional information about their child’s health
TRUMBULL, Conn. and EL MONTE, Calif. — CooperSurgical®, a global leader in fertility and women’s health, and Fulgent Genetics, Inc. (NASDAQ: FLGT), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced that they have partnered to offer families of Cord Blood Registry® (CBR®) exclusive newborn genetic screening panels. [Read more…]
Launch of the National Cord Blood Network to Optimize Life-Saving Treatment with Cord Blood Transplantation in Hematologic Malignancies
CLEVELAND, February 23, 2024 — The National Cord Blood Network (NCBN) proudly announces its official launch, signaling a new era of advances and collaboration in cord blood transplantation. The NCBN aims to increase accessibility to life-saving cord blood transplantation for patients with hematologic malignancies in US Transplant Centers as well as optimize cord blood transplant practices. [Read more…]
AVANT BIO Emerges as a Leading Equity Firm in Life Sciences, Tech Bio, and HealthTech
NEW YORK — AVANT BIO LLC, a pioneering early stage and growth equity firm, announces its official launch, positioning itself at the forefront of today’s transformative landscape in life sciences, tech bio, and healthtech industries. The Firm’s investments align with the convergence of groundbreaking technologies and an enhanced understanding of biology, creating a powerful synergy poised for breakthrough advancements in the future. [Read more…]
- « Previous Page
- 1
- …
- 32
- 33
- 34
- 35
- 36
- …
- 119
- Next Page »